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Objectives: To evaluate in a retrospective analysis the efficacy and safety of a 6 day course of liposo-
mal amphotericin B (L-AmB) in infantile cases of Mediterranean visceral leishmaniasis (VL) diagnosed
over a 10 year period in Italy.
Patients and methods: Patients included were diagnosed as having VL consecutively admitted from
December 1992 to December 2001 at four main referral children’s hospitals in Italy and treated with six
intravenous doses of 3 mg/kg L-AmB given on days 1–5 and 10 (a total dose of 18 mg/kg). Demo-
graphic data, nutritional status, underlying diseases, clinical and laboratory findings, and therapy out-
come were considered.
Results: A total of 164 HIV-negative children (median age 1.6 years; range 4 months to 14 years) were
enrolled. All patients were initially cured by the given treatment, and did not present adverse events
related to drug infusion. Seven patients (4.3%) had a clinical and parasitological relapse 3–15 months
after therapy. All relapses were successfully retreated with 3 mg/kg L-AmB for 10 consecutive days
(a total dose of 30 mg/kg).
Conclusions: This study highlights the efficacy (>95%) and safety of the six dose L-AmB regimen and
validates it as a first-line treatment for Mediterranean VL in children.
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Introduction
Visceral leishmaniasis (VL) is endemic in all the countries
bordering the Mediterranean basin, where it is caused by the
protozoan Leishmania infantum and is transmitted by the bite
of phlebotomine sandflies. Dogs are the proven reservoir of
infection.1
After their introduction in the therapy of VL in the early part
of the 20th century,2 pentavalent antimonial drugs have been
considered the standard treatment for VL for more than 60
years.3 They have been used extensively in children and have
been demonstrated to be generally safe and effective.4,5 How-
ever, during the last decade, the emergence in certain geo-
graphical areas of Leishmania strains resistant to pentavalent
antimonials, coupled with some drug toxicity and prolonged
administration, has prompted the evaluation of alternative drugs,
including lipid formulations of amphotericin B.3
Liposomal amphotericin B (L-AmB) is the only drug
approved by the US Food and Drug Administration for the
treatment of any VL (i.e. caused by Leishmania donovani,
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L. infantum or Leishmania chagasi) in immunocompetent
patients, with a regimen of seven infusions of 3 mg/kg given
on days 1–5, 14 and 21 (total dose 21 mg/kg).6 Results from a
dose-decreasing study have a shown that a short course of
L-AmB (six infusions of 3 mg/kg given on days 1–5 and 10;
total dose 18 mg/kg) could be safe and effective in treating
children with Mediterranean VL.7
We report here our 10 year experience with the use of this
short course of L-AmB for the treatment of paediatric VL in Italy.
Patients and methods
Four paediatric centres participated to the study. (i) The G. Di
Cristina Hospital in Palermo, which is the largest children’s hos-
pital in Sicily. It is a tertiary-care university hospital with 350
beds, and acts as referral paediatric centre for western Sicily. (ii)
The Santobono-Pausilipon Hospital for Children’s Diseases is a
high speciality structure, and represents an outstanding centre
for paediatric emergencies and many branches of paediatric
pathology for the southern Italian population. (iii) The Giannina
Gaslini Institute for the Cure, Protection and Care of Infants and
Children is classified as public Research Institute and Children’s
Hospital, and acts as referral paediatric centre for northern Italy.
(iv) Policlinico Umberto I, University ‘La Sapienza’ of Rome,
acts as referral paediatric centre for several areas of central Italy.
Children aged 0–14 years consecutively diagnosed as having
VL and treated with six infusions of 3 mg/kg L-AmB given
on days 1–5 and 10, during the period December 1992 to
December 2001 were evaluated. The patient’s clinical histories
were stored in a database that included demographic character-
istics, clinical and laboratory findings recorded on admission and
during hospitalizations, therapeutic interventions and clinical
outcome.
Diagnosis of VL was established if patients had at least one
of the following criteria: (i) presence of clinical signs and symp-
toms compatible with VL (fever, splenomegaly, pancytopenia,
hypergammaglobulinaemia) and detection of serum Leishmania
antibodies by immunofluorescent antibody test (IFAT) at a titre
>_1:40; and/or (ii) demonstration of Leishmania parasites in bone
marrow or spleen aspirates by microscopy and/or culture.
Fever was defined as a temperature >_38.08C; anaemia was
defined as a haemoglobin value of <9.0 mg/dL; leucopenia was
defined as <4000 white blood cells/mL; and thrombocytopenia
as <150 000 platelets/mL.
IFAT was performed using an in-house manufactured antigen
preparation (from the WHO reference strain of L. infantum)
or a commercial kit (Leishmania-Spot IF; bioMe´rieux, Marcy
l’E´toile, France). Cultures were performed by seeding bone mar-
row aspirates into blood agar media (Evans’ modified Tobie’s
medium and/or ‘sloppy’ Evans’ medium). Established positive
cultures were characterized by the electrophoretic analysis of 15
enzymatic loci, using the techniques and zymodeme nomencla-
ture of the WHO Collaborating Centre of Montpellier, France.8
Clinical response was assessed at the completion of treatment
on day 10, and was either initial cure (defined as defervescence,
restoration of laboratory parameters and reduction of spleen
size), or failure, which was defined as persistent or worsening
clinical and laboratory findings. A VL relapse was defined as
the recurrence of signs and symptoms of disease associated
with demonstration of Leishmania in bone marrow after initial
successful treatment. All the patients were followed at the hospi-
tal’s outpatient clinic for at least 6 months after treatment was
completed.
The t-test for dependent samples was computed to evaluate
the differences in clinical and laboratory data before (day 0) and
at the completion of (day 10) treatment. A two-tailed level of
P value <_0.05 was used for all analyses.
Results
In the 10 year period considered, 164 children met the inclusion
criteria. Thirty-seven (22.6%) had been enrolled in previous
clinical trials on L-AmB and have already been described.7,9,10
Seven patients (4.2%) had been previously treated for VL with
meglumine antimoniate, and had a relapse. Three patients
(1.8%) who had started on antimonial treatment were shifted
onto L-AmB because of poor response (two cases) or toxicity
(one case). In the remaining 117 patients (71.4%), L-AmB was
used as first-line treatment on the basis of the ongoing good
results obtained in the aforementioned studies on this drug.
The median age of patients was 1.6 years (range 4 months to
14 years); 42 patients (25.6%) were aged <12 months. Ninety-
one (54.1%) were males. HIV serology was negative in all
cases.
At admission, analysis of the nutritional status of the patients
showed that 27 (16.5%) were below the tenth percentile on the
weight-for-age growth chart. Twelve (7.3%) had underlying con-
ditions at hospital admission: one was affected by tetraparesis,
one by pseudomembranous conjunctivitis and 10 by thalassae-
mic trait. Concurrent bacterial or viral infections were diagnosed
in 10 patients (6.1%): seven had respiratory infections (two
bronchitis and five pneumonia), two rotavirus gastroenteritis and
one chickenpox.
The median time from the onset of symptoms to hospital
admission was 15 days (range 4–90 days). At admission, fever
and splenomegaly were present in all patients. Anaemia and
thrombocytopenia were frequently observed (77.5% and 67%
of patients, respectively); leucopenia was present in 27.8% of
cases, and a neutrophils count of <500/mL was found in 10.3%
of the patients. Pancytopenia was present in 19.6%, and an
association of leucopenia and thrombocytopenia without anae-
mia in 4.8% of cases. Albumin value was <3 g/dL in 24.2% of
cases, and 49.4% of patients showed inversion of A/G ratio. A
value for aspartate aminotransferase and alanine aminotransfer-
ase >80 IU/L was reported in 8.4% and 7.2% of cases, respect-
ively. An erythrocyte sedimentation rate >40 mm/h was found in
93.5% of patients (Table 1).
A bone marrow aspirate was obtained in all patients, and
Leishmania amastigotes were detected in 160 cases (97.6%).
Serology was performed and found to be positive in all of them,
with a geometric mean titre of anti-Leishmania antibodies of
661 (range 80–10 240). Hence, laboratory diagnosis of VL was
established by bone marrow microscopy in association with posi-
tive serology in 160 patients and by means of serology only in
the remaining four patients (2.4%).
Culture from bone marrow aspirate was performed in 112
patients and found to be positive in 96 (85.7%). Zymodeme ana-
lysis was carried out on 87 established isolates; 56 were charac-
terized as L. infantum zymodeme MON 1 (the most common
genotype in the Mediterranean area), 30 as L. infantum MON 72
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(the typical genotype of the Naples area) and one as L. infantum
MON 80.11
All 164 patients had initial cure with L-AmB treatment, with
no relevant adverse effects. Anaemic condition required blood
transfusion in 18 (11.0%). Defervescence occurred after a mean
of 43.8 ± 13 h (range 12–76 h) from the first L-AmB infusion.
Table 1 shows changes from baseline clinical and laboratory
results to those obtained at the end of treatment. Increase of red
blood cells, haemoglobin, neutrophils, platelets and albumin,
and reduction of spleen size, erythrocyte sedimentation rate
and C-reactive protein, were statistically significant on day 10
(P<0.0001). The duration of hospitalization was 8 ± 3 days
(range 5–27 days), with most of the cases being treated on day
10 as outpatients.
Patients were followed at the outpatient clinic for a median of
1 year (range 6 months to 3 years) after treatment was completed.
Seven patients (4.3%) had a VL relapse at 3, 4, 5, 5.5, 6, 13 and
15 months, respectively; hence, the definitive cure rate was
95.7%. All the relapsing patients were successfully re-treated
with L-AmB administered intravenously at a dosage of 3 mg/kg
for 10 consecutive days (total dose 30 mg/kg).
Discussion
Pentavalent antimony compounds (sodium stibogluconate and
meglumine antimoniate) have been considered the standard anti-
leishmanial treatment for >60 years, and, notwithstanding the
emergence of a high level of resistance in some parts of India
(especially in North Bihar), they are still the first-line drugs in the
other VL foci in the Indian subcontinent;12,13 however, antimo-
nials need a long period of hospitalization (3–4 weeks) and are
characterized by non-negligible adverse effects. In 1997, the US
Food and Drug Administration approved L-AmB for the treat-
ment of VL, with a regimen consisting of seven doses of 3 mg/kg
(total dose 21 mg/kg).6 In the same year, di Martino et al.7 showed
that in immunocompetent children with VL caused by L. infan-
tum, a lower total dose of L-AmB (i.e. 18 mg/kg given in six
doses over 10 days) had a high rate of response (95.8%), and pro-
posed this as the treatment schedule of choice.
In this uncontrolled, retrospective, multicentre study, we con-
firm and extend previous results regarding the efficacy and
safety of that 6 day schedule of L-AmB in a much larger
cohort of paediatric patients recruited in Palermo, Naples,
Genoa and Rome. Our findings indicate that a total dose of
18 mg/kg of L-AmB induces a cure rate of 95.7% for Mediter-
ranean VL in children, and is at least as effective as conven-
tional antimonial therapy. In fact, as reported in a recent large
retrospective study, the antimonial cure rate in Italy was found
to range from 90% to 95%.14 Moreover, several studies have
shown that time of defervescence, reduction in spleen size and
correction of haematological parameters occurs more quickly
among patients (adults and children) treated with L-AmB in
comparison with those treated with meglumine antimoniate.15,16
Increase of red blood cells and haemoglobin are an earlier
index of response to treatment, and reinforce the attitude of
waiting before carrying out transfusion.
The main objection to the use of L-AmB for the treatment of
VL in countries where resistance to antimonials has been rarely
reported is the high cost of the drug. In Italy, the wholesale
price of a 50 mg vial of L-AmB is e151, whereas that of a vial
of meglumine antimoniate containing 425 mg of antimonium is
almost negligible (about e0.7). In a 15 kg patient (the median
weight of our patients), the cost of the L-AmB regimen is about
e900; however, the high cost of the treatment is counterbalanced
by the reduction of the hospitalization period: assuming an aver-
age cost of e250 per day of hospital stay in Italy, the treatment
with L-AmB is more affordable than the 21 day hospitalization
period needed using antimonial therapy (e3031 versus e5265).
Recently, in Greece, a 2 day regimen of L-AmB
(10 mg/kg/day) was compared with a 5 day regimen of L-AmB
(4 mg/kg/day) and with a 30 day regimen of meglumine anti-
moniate, in an open, prospective study on infantile Mediterra-
nean VL. No differences in the response rates among the
comparison groups were observed, but the pharmacoeconomic
analysis showed a lower cost for patients treated with two doses
of L-AmB (e1664) compared with those treated with five doses
of L-AmB (e2284) or 30 doses of meglumine (20 mg/kg/day)
(e2600).16 However, it should be noted that this high dose given
in a 2 days regimen is not currently approved for this condition,
Table 1. Clinical, haematological and biochemical features of 164 children with VL before (day 0) and at the
completion of (day 10) treatment with L-AmB
Variables Day 0a Day 10a % Differenceb
Weight (kg) 14.1 ± 8.4 (5.9–71.5) 14.5 ± 8.7 (6–76) " 2 ± 4.6
Spleen size (cm from the left costal margin) 6 ± 2.4 (2–14) 3.5 ± 2 (0–10) # 40 ± 24.5
Red blood cells (106 cells/mL) 3.7 ± 0.5 (1.9–4.9) 4.2 ± 0.4 (2.2–5.4) " 13.8 ± 1.1
Haemoglobin (g/dL) 7.9 ± 1.4 (3.8–12) 9.5 ± 1.1 (5.7–14) " 16 ± 0.9
White blood cells (103 cells/mL) 5.3 ± 2.3 (1.8–14.7) 8.1 ± 2.7 (2.4–18.7) " 30.6 ± 1.9
Neutrophils (103 cells/mL) 1.2 ± 6.8 (0.2–5.4) 2 ± 1.4 (0.2–7.8) " 45 ± 55
Platelets (103 cells/mL) 119.8 ± 50 (18–311) 277.8 ± 101 (38–565) " 53.2 ± 23.6
Erythrocyte sedimentation rate (mm/h) 82.1 ± 27.4 (24–138) 44.2 ± 24.1 (7–138) # 43.2 ± 32
C-reactive protein (mg/100 mL) 12.9 ± 15.8 (0.7–76) 3.2 ± 9.6 (0–44) # 89.9 ± 12
Albumin (g/dL) 3.1 ± 0.5 (1.4–5.5) 3.5 ± 4.2 (2.4–4.9) " 11.5 ± 1.9
aValues are presented as means ± S.D. (range).
bThe direction of the arrow indicates whether the day 10 values were increased or decreased compared with the day 0 values. Values
are the means ± S.D. of the percentage differences between day 10 and day 0 values (computed using the paired data for each patient).
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and needs further demonstration of its good tolerability in
children. In India, a study conducted on 91 patients affected by
VL and employing a total dose of 5 mg/kg of L-AmB (adminis-
tered as a single infusion or as a 5 day infusion of 1 mg/kg
daily) showed a 92% cure rate, with a cost of US$519;17 how-
ever, for developing countries this cost, despite being more
affordable, is still considered too high. We are aware of only a
single case-report of Mediterranean VL treated with a single
dose of L-AmB.18 It should be remembered that regional differ-
ences in response to treatment have been observed, probably
related to the infecting Leishmania strain; in fact, Brazilian
infection caused by L. chagasi seems to be less responsive to
L-AmB than Indian Kala-azar (caused by L. donovani).19
In conclusion, our study confirms the safety and efficacy of
a total dose of 18 mg/kg for the treatment of Mediterranean VL
in children, but the same efficacy for VL acquired outside the
Mediterranean basin should not be inferred. Furthermore, in
developed countries, for the paediatric population, the reduction
of length of hospitalization seems to be cost-effective.
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